What the changes say
- Divestitures now create retained liabilities, indemnification, buyer disputes, stranded costs, customer loss, and litigation exposure.
- International customers generated approximately 20% of 2025 revenue, exposing expansion and margins to instability and currency movements.
- Supply-chain dependence includes single- and sole-source suppliers and third-party manufacturers.
- Newer exposures include AI deployment, tax-law changes and NOL expiration, and anti-corruption, competition, and sanctions compliance.
What changed since the prior 10-K
New
- NewRisks related to our business and operations
We are dependent on our suppliers and third-party manufacturers, including single-source and sole-source suppliers, and disruptions in our supply chain could adversely affect our ability to manufacture and deliver products
Single- and sole-source suppliers or third-party manufacturers could face operational, financial, quality, or regulatory problems that halt product production or delivery.
- NewRisks related to our business and operations
protection laws and regulations could impose significant limitations and increase our cost of providing our products and services where we process end user personal data and could harm our results of operations and expose us to significant fines, penalties, and other damages
Violations of foreign and U.S. anti-corruption, competition, sanctions, and related laws could bring fines, business restrictions, and higher compliance costs.
- NewRisks related to our acquisition and divestiture activities
Our recent divestitures expose us to ongoing risks and uncertainties, one or more of which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or stock price
Recent divestitures create retained liabilities, indemnification obligations, buyer disputes, stranded costs, customer and employee losses, and litigation exposure.
- NewRisks related to our acquisition and divestiture activities
These risks, or any future unforeseen risks, could have a material adverse impact on our business, financial condition, results of operations, cash flows or the price of our common stock
Divestitures have caused transaction, severance, settlement, and accelerated stock-compensation costs, with similar expenses possible from future divestitures.
- NewRisks related to our intellectual property, cyber security, and artificial intelligence
The development, deployment and use of AI technologies present new risks and challenges that could adversely impact our business
Immature, inaccurate, incomplete, flawed, or biased AI used in operations, products, technology, or services could cause liability, penalties, or reputational harm.
- NewRisks related to accounting matters
Changes in tax laws and regulations could adversely affect our financial condition and results of operations
Tax examinations or law changes could increase taxes, while insufficient profits before NOL expirations could prevent use of accumulated tax losses.
- NewRisks related to disruptive events
As we increase sales in international markets, any such international instability and reduction in global trade could negatively impact our expansion plans and international sales. Such risks may also affect our customers’ budgets and their policies which may adversely affect our sales revenue
International instability, trade restrictions, customer budget changes, and currency fluctuations could reduce overseas sales or pressure prices and margins; international customers supplied approximately 20% of 2025 revenue.
Dropped
- DroppedRisks related to our business and operations
We depend on outside suppliers for all our manufacturing supplies, parts and components
- DroppedRisks related to our business and operations
attract such key management personnel and the loss of one or more of these individuals could have a material adverse effect on our business and operating results
- DroppedRisks related to our acquisition strategy
profitable. Our failure to successfully address the foregoing integration risks may prevent us from achieving the anticipated benefits from any acquisition in a reasonable time frame, or at all
Reworded
- 85% rewrittenRisks related to disruptive events
Tariffs and other trade policies could have a substantial impact on our business
The update adds 2025 and first-quarter 2026 tariff developments, temporary tariff suspensions or reductions, and resulting foreign retaliation.
- 64% rewrittenRisks related to our business and operations
Our success will depend on our ability to attract and retain key personnel
The risk now expressly includes engineering, scientific, sales, and technical personnel, beyond executive and key management retention.
- 49% rewrittenRisks related to disruptive events
Natural disasters, geopolitical unrest, war, terrorism, public health issues or other catastrophic events could disrupt the supply, delivery or demand of products, which could negatively affect our operations and performance
The update adds government shutdowns and names the Ukraine war, Middle East conflict, and recent U.S. involvement in Venezuela.
- 48% rewrittenRisks related to accounting matters
The aforementioned material weaknesses did not result in any identified material misstatements to our financial statements, and there were only immaterial changes to previously released financial results
Remediation is now described as implemented rather than begun, and late SEC or Nasdaq filings are identified as additional consequences.
- 38% rewrittenRisks related to our business and operations
While we are not currently subject to FDA or other regulatory approvals, if our products become subject to regulatory requirements, the manufacture and sale of our products may be delayed or prevented, or we may become subject to increased expenses
No substantive change is shown in the provided text; the FDA and foreign regulatory-approval discussion is unchanged.
- 29% rewrittenRisks related to our acquisition and divestiture activities
Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies
No substantive change is shown in the provided excerpt; acquisition integration and operational challenges remain the focus.
- 25% rewrittenRisks related to our common stock
A significant percentage of our outstanding common stock is held by one stockholder, and this stockholder therefore has significant influence on us and our corporate actions
Casdin Capital’s reported ownership fell from 8,707,165 shares and 18.6% to 5,957,165 shares and 12.4%.
All 37 risk factors
Headings as the filing states them, in filing order.
Risks related to our business and operations
- 01If our products or the products of our competitors do not perform as expected or the reliability of the technology on which our products are based is questioned, we could experience lost revenue, delayed or reduced market acceptance of our products, increased costs, and damage to our reputation
- 02We operate in a highly competitive industry and if we cannot compete effectively, our business, financial condition and operating results could be materially and adversely affected
- 03We expect our operating results to fluctuate significantly from period to period
- 04If intangible assets and goodwill become impaired, we may have to take significant charges against earnings
- 05Our success will depend on our ability to attract and retain key personnel64% rewritten
- 06Our business may be subject to product liability claims or product recalls, which could be expensive and could result in a diversion of management’s attention
- 07Difficulties in manufacturing could have an adverse effect upon our expenses and our product revenues
- 08We are dependent on our suppliers and third-party manufacturers, including single-source and sole-source suppliers, and disruptions in our supply chain could adversely affect our ability to manufacture and deliver productsNew
- 09While we are not currently subject to FDA or other regulatory approvals, if our products become subject to regulatory requirements, the manufacture and sale of our products may be delayed or prevented, or we may become subject to increased expenses38% rewritten
- 10protection laws and regulations could impose significant limitations and increase our cost of providing our products and services where we process end user personal data and could harm our results of operations and expose us to significant fines, penalties, and other damagesNew
- 11Healthcare reform measures could adversely affect our business and financial results
- 12Insurance coverage is increasingly difficult to obtain or maintain
- 13We are and may become the subject of various claims, litigation or investigations which could have a material adverse effect on our business, financial condition, or results of operations or the price of our common stock
- 14Our business and operations could be negatively affected by securities litigation or stockholder activism, which could impact the trading price and volatility of our common stock and may constrain capital deployment opportunities and adversely impact our ability to expand our business
Risks related to our acquisition and divestiture activities
- 15Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies29% rewritten
- 16Our recent divestitures expose us to ongoing risks and uncertainties, one or more of which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or stock priceNew
- 17These risks, or any future unforeseen risks, could have a material adverse impact on our business, financial condition, results of operations, cash flows or the price of our common stockNew
Risks related to our intellectual property, cyber security, and artificial intelligence
- 18Our proprietary rights may not adequately protect our technologies and products
- 19Expiration of our patents may subject us to increased competition and reduce our opportunity to generate product revenue
- 20We may not be able to protect our intellectual property rights throughout the world
- 21We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be unable to protect our rights to, or use of, our technology
- 22Even if we are granted a patent, in certain circumstances we may be unable to protect our rights to, or use of, our technology
- 23U.S. patent laws as well as the laws of some foreign jurisdictions provide for provisional rights in published patent applications beginning on the date of publication, including the right to obtain reasonable royalties, if a patent subsequently issues and certain other conditions are met
- 24We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
- 25The development, deployment and use of AI technologies present new risks and challenges that could adversely impact our businessNew
Risks related to our common stock
- 26Our stock price and volume may be volatile, and purchasers of our securities could incur substantial losses
- 27A significant percentage of our outstanding common stock is held by one stockholder, and this stockholder therefore has significant influence on us and our corporate actions25% rewritten
- 28We have not paid dividends on our common stock in the past and do not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock
- 29Certain provisions in our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
- 30Furthermore, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the sole and exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act
Risks related to accounting matters
- 31The aforementioned material weaknesses did not result in any identified material misstatements to our financial statements, and there were only immaterial changes to previously released financial results48% rewritten
- 32Changes in tax laws and regulations could adversely affect our financial condition and results of operationsNew
Risks related to disruptive events
- 33Natural disasters, geopolitical unrest, war, terrorism, public health issues or other catastrophic events could disrupt the supply, delivery or demand of products, which could negatively affect our operations and performance49% rewritten
- 34Tariffs and other trade policies could have a substantial impact on our business85% rewritten
- 35As we increase sales in international markets, any such international instability and reduction in global trade could negatively impact our expansion plans and international sales. Such risks may also affect our customers’ budgets and their policies which may adversely affect our sales revenueNew
- 36Public health crises have adversely affected, and could in the future adversely affect, our business, financial condition. results of operations and cash flows
- 37Global climate change and related legal and regulatory developments could negatively affect our business, financial condition and results of operations
Other Biolife Solutions 10-Ks
- FY2024 10-K risk factors33 risks
Single-source suppliers manufacture critical bioproduction components for cell and gene therapies.
Filed Mar 03, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.